Laninamivir-Interferon Lambda 1 Combination Treatment Promotes Resistance by Influenza A Virus More Rapidly than Laninamivir Alone-Reference-Cited by-同舟云学术

Laninamivir-Interferon Lambda 1 Combination Treatment Promotes Resistance by Influenza A Virus More Rapidly than Laninamivir Alone

Published:2020-06-23 Issue:7 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Adams Simone E.¹,Lugovtsev Vladimir Y.²,Kan Anastasia²,Bovin Nicolai V.³,Donnelly Raymond P.¹^ORCID,Ilyushina Natalia A.¹^ORCID

Affiliation:

1. Division of Biotechnology Review and Research II, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA

2. Division of Viral Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA

3. Laboratory of Carbohydrates, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia

Abstract

Each year, 5% to 20% of the population of the United States becomes infected with influenza A virus. Combination therapy with two or more antiviral agents has been considered a potential treatment option for influenza virus infection. However, the clinical results derived from combination treatment with two or more antiviral drugs have been variable. We examined the effectiveness of cotreatment with two distinct classes of anti-influenza drugs, i.e., neuraminidase (NA) inhibitor, laninamivir, and interferon lambda 1 (IFN-λ1), against the emergence of drug-resistant virus variants in vitro .

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00301-20

Reference56 articles.

1. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study

2. Drug resistance in influenza A virus: the epidemiology and management

3. Zanamivir-Resistant Influenza Viruses with a Novel Neuraminidase Mutation

4. Update: influenza activity—United States, September 28, 2008–April 4, 2009, and composition of the 2009–10 influenza vaccine;Centers for Disease Control and Prevention;Morb Mortal Wkly Rep,2009

5. E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Retracted and republished from: “The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs”;mBio;2024-05-08

2. Tackling Influenza A virus by M2 ion channel blockers: Latest progress and limitations;European Journal of Medicinal Chemistry;2024-03

3. The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs;mBio;2023-10-31

4. Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy;Microorganisms;2023-01-11

5. Generation and characterization of interferon-beta-resistant H1N1 influenza A virus;Acta virologica;2022